CJC-1295 + Ipamorelin: Growth Hormone Peptide Research Guide 2026

Disclaimer: This article is for informational and research purposes only. CJC-1295 and Ipamorelin are research peptides not approved for human therapeutic use. All information is derived from published preclinical and clinical research literature. Consult applicable regulations before conducting research with these compounds.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates the anterior pituitary gland to synthesize and secrete growth hormone (GH). CJC-1295 consists of 29 amino acids — a modified version of the first 29 residues of human GHRH(1-29), also known as Sermorelin — with four amino acid substitutions at positions 2, 8, 15, and 27 designed to enhance its resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV).

The modifications in CJC-1295 confer significantly improved metabolic stability compared to native GHRH, which has a plasma half-life of only 5–7 minutes. In its unmodified form (often designated "CJC-1295 without DAC" or "Mod GRF 1-29"), the peptide achieves a half-life of approximately 30 minutes — a substantial improvement that allows for more practical dosing intervals in research settings.

Drug Affinity Complex (DAC) Technology

A further modification involves conjugating CJC-1295 to a Drug Affinity Complex (DAC) — a reactive chemical entity (maleimidopropionic acid linked to a lysine spacer) that binds covalently and irreversibly to serum albumin after injection. This albumin binding dramatically extends the circulating half-life to 6–8 days, creating a sustained-release growth hormone secretagogue that can elevate GH and insulin-like growth factor-1 (IGF-1) levels for extended periods from a single administration.

CJC-1295 DAC was originally developed by ConjuChem Biotechnologies and underwent clinical evaluation in the mid-2000s. The compound reached Phase II clinical trials before development was paused for commercial and strategic reasons rather than safety or efficacy concerns. The published clinical data from these trials remains an important resource for researchers studying growth hormone peptides.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts through a mechanism distinct from CJC-1295. While CJC-1295 mimics the action of GHRH at the GHRH receptor (GHRH-R), Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. This receptor is the same target engaged by the endogenous hunger hormone ghrelin and by other synthetic GH secretagogues such as GHRP-6, GHRP-2, and hexarelin.

Structure and Selectivity

Ipamorelin's sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporates several non-natural amino acid modifications that confer both metabolic stability and remarkable receptor selectivity. Among GHS-R1a agonists, Ipamorelin is distinguished by its high selectivity for growth hormone release with minimal stimulation of other pituitary hormones. Published research has demonstrated that Ipamorelin produces dose-dependent GH release without significantly elevating adrenocorticotropic hormone (ACTH), cortisol, or prolactin — a selectivity profile superior to earlier GH secretagogues such as GHRP-6 and hexarelin.

Pharmacological Profile

Ipamorelin was initially developed by Novo Nordisk and later licensed to other pharmaceutical entities. Clinical trials in post-surgical patients evaluated its ability to accelerate recovery through GH-mediated anabolic effects. The peptide demonstrated dose-dependent GH release in human subjects, with peak GH levels occurring approximately 40 minutes after subcutaneous administration and returning to baseline within 2–3 hours.

This pharmacokinetic profile — a distinct GH pulse followed by return to baseline — closely mimics the natural pulsatile pattern of GH secretion, which is considered physiologically more appropriate than the sustained elevation produced by exogenous GH administration or long-acting secretagogues.

Synergistic Mechanisms

The combination of CJC-1295 and Ipamorelin has become one of the most widely studied peptide pairings in growth hormone research. Their synergy is rooted in the complementary pharmacology of their receptor targets and their interaction with the natural regulatory systems governing GH secretion.

Dual-Receptor Activation

Growth hormone secretion from somatotroph cells in the anterior pituitary is regulated by the interplay of two stimulatory signals and one inhibitory signal:

• GHRH (stimulatory): Binds the GHRH receptor and directly activates cAMP-mediated signaling pathways that promote GH gene transcription and GH vesicle exocytosis.
• Ghrelin/GHS-R1a agonists (stimulatory): Bind the GHS-R1a receptor and activate phospholipase C/IP3/calcium signaling, which amplifies the somatotroph's responsiveness to GHRH stimulation.
• Somatostatin (inhibitory): Tonically inhibits GH release by suppressing both cAMP and calcium signaling in somatotrophs.

When CJC-1295 (a GHRH analog) and Ipamorelin (a GHS-R1a agonist) are co-administered, they activate both stimulatory pathways simultaneously. Published research in animal models has demonstrated that this dual activation produces a GH release response that is greater than the sum of the individual peptide responses — a phenomenon termed synergistic amplification. Studies in rat pituitary cell preparations showed that combined GHRH and GHS-R1a activation produced GH release approximately 3-fold greater than either stimulus alone.

Preservation of Pulsatility

One of the most significant advantages of the CJC-1295 (without DAC) + Ipamorelin combination is the preservation of pulsatile GH release. Both peptides produce discrete GH pulses followed by a return to baseline, which maintains the sensitivity of the GH axis and prevents receptor desensitization. This is in contrast to continuous GH elevation (produced by exogenous recombinant GH or CJC-1295 DAC), which can suppress endogenous GH production through negative feedback and GH receptor downregulation.

Somatostatin Interaction

Research suggests that GHS-R1a agonists such as Ipamorelin may functionally antagonize somatostatin's inhibitory effects on GH release. This means that Ipamorelin may partially overcome the somatostatin tone that normally gates GHRH-stimulated GH secretion, further enhancing the combined response. This interaction is thought to contribute to the reliable, robust GH pulses observed with the CJC-1295 + Ipamorelin combination even in older animals and in conditions of elevated somatostatin activity.

Growth Hormone Research

Growth hormone is a 191-amino-acid protein with profound effects on metabolism, body composition, tissue repair, and cellular regeneration. Understanding the role of GH in these processes provides context for why CJC-1295 + Ipamorelin has attracted substantial research attention.

GH and IGF-1 Axis

Many of GH's downstream effects are mediated through insulin-like growth factor-1 (IGF-1), which is produced primarily by the liver in response to GH stimulation. The GH/IGF-1 axis influences:

• Protein synthesis: GH and IGF-1 stimulate protein synthesis in skeletal muscle, supporting muscle mass maintenance and repair. Research in GH-deficient models has demonstrated significant increases in lean body mass following GH restoration.
• Fat metabolism: GH promotes lipolysis (fat breakdown) and inhibits lipogenesis (fat storage), redirecting energy substrates toward protein synthesis. This partitioning effect is well-documented in both animal and human studies.
• Bone metabolism: IGF-1 stimulates osteoblast proliferation and differentiation, supporting bone mineral density. Clinical studies in GH-deficient adults have shown improvements in bone density with GH replacement therapy.
• Tissue repair: The GH/IGF-1 axis accelerates wound healing, connective tissue repair, and collagen synthesis. Surgical recovery studies have explored the potential of GH-mediated recovery acceleration.
• Sleep quality: GH secretion is closely linked to slow-wave sleep (SWS), and GH secretagogues have been shown to modulate sleep architecture in research settings.

Age-Related GH Decline

GH secretion peaks during puberty and declines progressively with age — a phenomenon termed somatopause. By age 60, GH levels may be 50–70% lower than peak values. This decline is associated with age-related changes in body composition (increased adiposity, decreased lean mass), reduced bone density, decreased exercise capacity, and impaired tissue repair.

The age-related decline in GH has motivated extensive research into secretagogue peptides as a potential means of restoring more youthful GH pulsatility. CJC-1295 + Ipamorelin is of particular interest because it stimulates endogenous GH production through natural signaling pathways rather than introducing exogenous hormone, potentially maintaining regulatory feedback mechanisms that exogenous GH administration bypasses.

CJC-1295 DAC vs. No-DAC

The distinction between CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29) is critically important for researchers designing growth hormone studies, as the two forms have fundamentally different pharmacokinetic and pharmacodynamic profiles.

CJC-1295 with DAC

The DAC-conjugated form creates a sustained-release depot effect through albumin binding. Key characteristics include:

• Half-life: 6–8 days, due to albumin conjugation preventing renal clearance and enzymatic degradation.
• GH elevation pattern: Sustained elevation of GH and IGF-1 levels over days. In clinical trials, a single 60 µg/kg dose produced persistent GH elevation for 6+ days and IGF-1 elevation for 9–11 days.
• Pulsatility: Blunted. The sustained GHRH-receptor stimulation overrides normal pulsatile dynamics, producing a more tonic GH elevation pattern.
• Clinical data: Phase II trials demonstrated dose-dependent increases in IGF-1 with once- or twice-weekly dosing. IGF-1 levels increased by 46–100% above baseline depending on dose and duration.
• Potential concern: Sustained GH/IGF-1 elevation may suppress endogenous GH production through negative feedback and may carry different risk profiles than pulsatile stimulation. Some researchers have noted the theoretical concern that prolonged IGF-1 elevation could have proliferative effects on susceptible tissues.

CJC-1295 without DAC (Mod GRF 1-29)

The non-DAC form retains the DPP-IV-resistant amino acid substitutions but does not bind albumin. Key characteristics include:

• Half-life: Approximately 30 minutes.
• GH elevation pattern: Produces a discrete GH pulse within 15–30 minutes that returns to baseline within 2–3 hours.
• Pulsatility: Preserved. Each administration mimics a natural GHRH signal, producing a GH pulse consistent with normal physiological patterning.
• Combination use: The no-DAC form is the standard version used in combination with Ipamorelin, as both compounds produce pulsatile GH release that complements natural secretory dynamics.
• Dosing frequency: Multiple daily administrations (typically 2–3 per day) required in research protocols, due to the shorter half-life.

Which Form for Which Research Question?

Researchers studying chronic GH/IGF-1 elevation effects may find CJC-1295 DAC advantageous for its dosing convenience and sustained pharmacology. Researchers studying pulsatile GH dynamics, combination secretagogue protocols, or physiological GH restoration models will generally prefer CJC-1295 without DAC paired with Ipamorelin. The choice should be driven by the specific research question and the biological model being investigated.

Published Research Data

The evidence base for CJC-1295 and Ipamorelin includes both preclinical studies and human clinical trial data, providing a more translatable foundation than many other peptides under investigation.

CJC-1295 Clinical Trials

The most substantive clinical data for CJC-1295 comes from ConjuChem Biotechnologies' Phase I/II program for the DAC-conjugated form. Key findings from published studies include:

• Dose-dependent GH and IGF-1 response: Single subcutaneous doses ranging from 30–60 µg/kg produced dose-proportional increases in mean GH levels and area-under-the-curve (AUC) GH values. IGF-1 levels increased in a dose-dependent manner and remained elevated for 9–11 days.
• Multi-dose studies: Weekly or biweekly dosing over 4–12 weeks demonstrated sustained IGF-1 elevation without significant tachyphylaxis (loss of response over time). IGF-1 remained within the upper-normal physiological range at the doses studied.
• Body composition trends: Preliminary body composition data showed trends toward increased lean body mass and decreased fat mass, consistent with the expected effects of GH/IGF-1 elevation, though the studies were not powered for these endpoints.

Ipamorelin Clinical Data

Ipamorelin's clinical development focused on post-operative recovery applications. Published findings include:

• GH release specificity: In healthy human volunteers, Ipamorelin produced dose-dependent GH release without significant effects on ACTH, cortisol, prolactin, FSH, LH, or TSH. This selectivity was confirmed across multiple studies and dose levels.
• Post-surgical studies: In patients undergoing abdominal surgery, Ipamorelin infusion was studied for its ability to accelerate bowel function recovery. Results showed trends toward faster return of bowel motility in Ipamorelin-treated patients, though outcomes varied across different surgical populations.
• Safety in human subjects: Across published clinical studies, Ipamorelin was well-tolerated, with adverse events limited to mild, transient injection-site reactions and occasional headache at higher doses.

Combination Data

Direct clinical trial data for the specific CJC-1295 (without DAC) + Ipamorelin combination is limited, as most clinical studies examined each peptide independently. However, the robust preclinical evidence for GHRH + GHS-R1a agonist synergy, combined with the individual clinical safety and efficacy profiles of each compound, provides a strong scientific rationale for the combination. In vitro studies using isolated pituitary preparations and in vivo studies in multiple animal species have consistently demonstrated synergistic GH amplification when GHRH analogs are paired with GHS-R1a agonists.

Comparison with Other GH Secretagogues

The growth hormone secretagogue landscape includes several compounds, each with distinct profiles. Understanding these differences helps researchers select the most appropriate compounds for their specific study objectives.

GHRP-6 (Growth Hormone Releasing Peptide-6)

GHRP-6 is a hexapeptide GHS-R1a agonist and one of the earliest synthetic GH secretagogues. It produces robust GH release but has significant side effects that limit its research utility:

• Appetite stimulation: GHRP-6 strongly stimulates appetite through ghrelin-receptor-mediated mechanisms, which can confound metabolic and body composition studies.
• Cortisol elevation: Unlike Ipamorelin, GHRP-6 produces measurable increases in cortisol and ACTH, introducing a catabolic and immunomodulatory variable that complicates interpretation of anabolic outcome measures.
• Prolactin elevation: GHRP-6 can elevate prolactin levels, which may influence reproductive and metabolic parameters in long-term studies.

GHRP-2

GHRP-2 is considered a more potent GH secretagogue than GHRP-6, producing higher peak GH levels per microgram of peptide. However, it shares GHRP-6's tendency to elevate cortisol and prolactin, albeit to a lesser degree. For studies where maximal GH stimulation is the primary objective, GHRP-2 may be preferred, but its broader hormonal effects must be accounted for in study design.

Hexarelin

Hexarelin is the most potent GHS-R1a agonist in terms of acute GH release magnitude. However, it shows rapid tachyphylaxis with repeated dosing — GH responses diminish significantly within days of continuous administration. This limits its utility in chronic dosing protocols. Hexarelin also produces the most pronounced cortisol and prolactin elevations among the common GH secretagogues.

MK-677 (Ibutamoren)

MK-677 is a non-peptide, orally bioavailable GHS-R1a agonist. Its oral bioavailability and long half-life (approximately 24 hours) make it convenient for chronic dosing studies. However, its sustained action produces more tonic than pulsatile GH elevation, and it shares GHRP-6's appetite-stimulating and cortisol-elevating effects. MK-677 has accumulated substantial clinical data including a landmark 2-year study in elderly subjects that demonstrated sustained IGF-1 elevation without significant safety concerns.

Why CJC-1295 + Ipamorelin

The CJC-1295 (no DAC) + Ipamorelin combination is favored in many research settings because it offers:

• Synergistic GH amplification through dual-receptor activation.
• Preserved pulsatile GH dynamics that mimic physiological secretion patterns.
• Minimal off-target hormonal effects (no significant cortisol, prolactin, or ACTH elevation).
• Well-characterized safety profiles for both individual components from human clinical trials.
• Adjustable dosing frequency and timing, allowing researchers to model different GH secretory patterns.

Safety Profile

The safety profiles of CJC-1295 and Ipamorelin have been evaluated in both preclinical and clinical settings, providing a more comprehensive safety database than exists for many research peptides.

CJC-1295 Safety Data

In published clinical trials, CJC-1295 (DAC form) was administered to over 100 human subjects across multiple dosing cohorts. Reported adverse events were generally mild and included:

• Injection site reactions (redness, swelling) — most common, generally transient.
• Headache — reported at higher doses.
• Diarrhea — infrequent, typically mild.
• Flushing and warmth — noted in some subjects shortly after injection.

No serious adverse events attributable to CJC-1295 were reported in published clinical trials. Hematology, clinical chemistry, and vital sign parameters remained within normal ranges throughout study periods. However, the total duration of human exposure in published studies is relatively limited (up to 12 weeks), and longer-term safety data would be needed to characterize chronic-use risk profiles.

Ipamorelin Safety Data

Ipamorelin has undergone more extensive clinical evaluation, with studies in both healthy volunteers and surgical patients. The safety profile has been consistently favorable:

• No clinically significant effects on cortisol, prolactin, ACTH, FSH, LH, or TSH at therapeutic doses.
• Mild, transient adverse events similar to CJC-1295 (injection site reactions, occasional headache).
• No dose-limiting toxicities identified across the studied dose range.
• No significant effects on glucose homeostasis or insulin sensitivity in short-term studies.

Theoretical Considerations

While the clinical safety data for both peptides is reassuring, researchers should be aware of theoretical considerations that warrant monitoring in long-term studies:

• IGF-1 and proliferative risk: Sustained elevation of IGF-1 levels has been associated in epidemiological studies with increased risk of certain cancers. While the secretagogue-induced IGF-1 elevation reported in clinical trials remained within physiological ranges, this association warrants consideration in long-term study design.
• Glucose metabolism: GH is a counter-regulatory hormone to insulin, and sustained GH elevation can impair glucose tolerance. Monitoring glucose and insulin sensitivity is advisable in chronic dosing protocols.
• Fluid retention: GH promotes sodium and water retention, which can manifest as peripheral edema or carpal tunnel-like symptoms. These effects are typically dose-dependent and reversible.

Dosing in Research Literature

Published research provides guidance on dosing parameters for both CJC-1295 and Ipamorelin, though researchers should note that optimal dosing may vary by species, model system, and research objective.

CJC-1295 with DAC

Clinical trial dosing for CJC-1295 DAC ranged from 30 to 60 µg/kg body weight, administered subcutaneously once or twice weekly. The 60 µg/kg once-weekly dose produced robust IGF-1 elevation (approximately 46–100% above baseline) sustained over 7+ days. In preclinical rodent studies, doses of 50–200 µg/kg were used, though direct extrapolation to human-equivalent doses requires allometric scaling.

CJC-1295 without DAC (Mod GRF 1-29)

The non-DAC form has been studied at doses of 1–2 µg/kg subcutaneously in human pharmacokinetic/pharmacodynamic studies. Due to its 30-minute half-life, research protocols typically employ 2–3 daily administrations to produce multiple GH pulses. In preclinical settings, saturation analysis suggests that receptor-saturating doses produce maximal GH pulse amplitudes, with additional dose increases providing diminishing returns.

Ipamorelin

Clinical dosing for Ipamorelin has been studied across a range from 0.01 to 0.1 mg/kg intravenously and 0.03 to 0.1 mg/kg subcutaneously. Dose-dependent GH release was observed across this range, with 0.03 mg/kg SC producing clinically relevant GH pulses with minimal side effects. In post-surgical studies, continuous infusion at 0.01 mg/kg/hour was used over several days.

Combination Dosing

While standardized clinical combination dosing has not been established, research protocols in the literature and in investigator-initiated studies have explored concurrent subcutaneous administration of CJC-1295 (without DAC) and Ipamorelin 2–3 times daily. The rationale for pre-sleep administration includes capitalizing on the natural nocturnal GH secretory peak and avoiding the confounding influence of postprandial insulin elevation, which suppresses GH secretion through somatostatin activation.

Important Dosing Principles

Several principles from the literature should guide dosing decisions in research settings:

• Diminishing returns: GH secretagogue dose-response curves typically plateau at moderate doses. Supramaximal dosing does not proportionally increase GH release and may introduce unnecessary risk or receptor desensitization.
• Timing relative to meals: GH secretagogue administration should be separated from food intake in research protocols. Postprandial hyperinsulinemia and hyperglycemia suppress GH release through somatostatin-mediated negative feedback, reducing the GH pulse amplitude.
• Pulsatile scheduling: For the no-DAC form + Ipamorelin combination, spacing doses to allow GH to return to baseline between pulses (at least 2–3 hours) is recommended to maintain somatotroph responsiveness and prevent desensitization.

Conclusion

The CJC-1295 + Ipamorelin combination represents one of the most well-characterized and scientifically rational approaches to growth hormone research. By simultaneously engaging both GHRH and GHS-R1a signaling pathways, this peptide pairing produces synergistic GH amplification while preserving physiological pulsatile dynamics and minimizing off-target hormonal effects.

The distinction between CJC-1295 with DAC and without DAC is critical for research design. The DAC form offers dosing convenience and sustained GH/IGF-1 elevation for studies requiring chronic exposure, while the no-DAC form paired with Ipamorelin provides the pulsatile dynamics that more closely model physiological GH secretion.

Published clinical data for both peptides individually — and robust preclinical data for their combined use — provides a strong evidence base for researchers. Safety profiles are favorable across short- and medium-term studies, though long-term monitoring of IGF-1 levels, glucose homeostasis, and proliferative risk markers remains advisable.

For researchers investigating growth hormone peptides, compound quality is paramount. Impure or misidentified secretagogues will produce unreliable pharmacodynamic data and may introduce confounding biological effects. NorPept provides research-grade CJC-1295 (both DAC and no-DAC forms) and Ipamorelin with comprehensive third-party analytical documentation, supporting the rigorous, reproducible science that advances the field.

CJC-1295 and Ipamorelin are research compounds intended for laboratory investigation only. They are not approved for human therapeutic use, athletic performance enhancement, or self-administration. All research must comply with applicable institutional, local, and national regulations.